MDPK67b / Med Discovery - LARVOL DELTA

Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins. (PubMed, Prostate Cancer) - P1 | "By inhibition with the recombinant protease inhibitor MDPK67b targeting KLK2 and other trypsin-like KLKs including KLK4 and KLK14, we investigated the antitumor response and the influence on AR downstream target genes with MDPK67b in PCa cell lines in vitro...Therefore, inhibition of KLKs represents a promising and AR-independent approach to treat advanced and CRPCa. ClinicalTrials.gov ID: NCT04644770."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • ANXA5 • AR • KLK2 • KLK3

MDPK67b in Patients With Prostate Cancer (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Med Discovery SA | Trial completion date: Aug 2023 ➔ Jun 2024 | Trial primary completion date: Aug 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • AR • KLK2